Download PDF
Semin Respir Crit Care Med 2005; 26(6): 643-649
DOI: 10.1055/s-2005-925528
Published © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Staphylococcus aureus Pneumonia: Emergence of MRSA in the Community

Suzanne F. Bradley1 , 2
  • 1Department of Internal Medicine, Divisions of Infectious Diseases and Geriatric Medicine, University of Michigan Medical School, Ann Arbor, Michigan
  • 2Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
30 December 2005 (online)

    Permissions and Reprints

ABSTRACT

The clinical presentation of staphylococcal pneumonia is changing. Healthy young people without traditional risk factors for Staphylococcus aureus disease are presenting with severe necrotizing infection and high mortality. The clinical picture is reminiscent of outbreaks of postinfluenzal staphylococcal pneumonia seen in the past century. Most of these staphylococcal strains are methicillin-resistant and are not health care associated. Many strains contain toxins that are likely responsible for the severity of illness seen. Panton-Valentine leukocidin has rarely been identified in S. aureus until recently. It appears that the genetic element for methicillin resistance has been introduced into multiple highly virulent methicillin-susceptible strains with great potential for further spread. Early recognition and treatment of possible community-acquired methicillin-resistant S. aureus (CA-MRSA) is essential. It is equally important to attain microbiological confirmation of the diagnosis for optimal treatment and to initiate appropriate infection control procedures.

KEYWORDS

Methicillin resistance - pneumonia - staphylococci

REFERENCES

  • 1 Garner J S, Jarvis W R, Emori T G et al.. CDC definitions for nosocomial infections.  Am J Infect Control. 1988;  16 128-140
    CrossrefPubMedGoogle Scholar
  • 2 Cookson B D. Methicillin-resistant Staphylococcus aureus in the community: new battlefronts, or are the battles lost?.  Infect Control Hosp Epidemiol. 2000;  21 398-403
    PubMedGoogle Scholar
  • 3 Zetola N, Francis J S, Nuermberger E L, Bishai W R. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat.  Lancet Infect Dis. 2005;  5 275-286
    CrossrefPubMedGoogle Scholar
  • 4 Salgado C D, Farr B M, Calfee D P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors.  Clin Infect Dis. 2003;  36 131-139
    CrossrefPubMedGoogle Scholar
  • 5 Saravolatz L D, Pohlod D J, Arking L M. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks.  Ann Intern Med. 1982;  97 325-329
    PubMedGoogle Scholar
  • 6 Centers for Disease Control and Prevention . Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999.  Morb Mortal Wkly Rep. 1999;  48 707-710
    PubMedGoogle Scholar
  • 7 Herold B C, Immergluck L C, Maranan M C et al.. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.  JAMA. 1998;  279 593-598
    CrossrefPubMedGoogle Scholar
  • 8 Said-Salim B, Mathema B, Kreiswirth B N. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen.  Infect Control Hosp Epidemiol. 2003;  4 451-455
    PubMedGoogle Scholar
  • 9 Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey.  Clin Infect Dis. 2005;  40 562-573
    CrossrefPubMedGoogle Scholar
  • 10 Mongkolrattanothai K, Boyle S, Kahanna M D et al.. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates.  Clin Infect Dis. 2003;  37 1050-1058
    CrossrefPubMedGoogle Scholar
  • 11 Chambers H F. Community-associated MRSA-resistance and virulence converge.  N Engl J Med. 2005;  352 1485-1487
    CrossrefPubMedGoogle Scholar
  • 12 Urth T, Juul G, Skov R et al.. Spread of methicillin-resistant Staphylococcus aureus ST80-IV clone in a Danish community.  Infect Control Hosp Epidemiol. 2005;  26 144-149
    PubMedGoogle Scholar
  • 13 Hausmann W, Karlish A J. Staphylococcal pneumonia in adults.  BMJ. 1956;  2 845-847
    PubMedGoogle Scholar
  • 14 Kaye M G, Fox M J, Bartlett J G et al.. The clinical spectrum of Staphylococcus aureus pulmonary infection.  Chest. 1990;  97 788-792
    PubMedGoogle Scholar
  • 15 Laupland K B, Church D L, Mucenski M et al.. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections.  J Infect Dis. 2003;  187 1452-1459
    CrossrefPubMedGoogle Scholar
  • 16 Musher D M, Lamm N, Darouiche R O et al.. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital.  Medicine. 1994;  73 186-208
    PubMedGoogle Scholar
  • 17 Fridkin S K, Hageman J C, Morrison M et al.. Methicillin-resistant Staphylococcus aureus in three communities.  N Engl J Med. 2005;  352 1436-1444
    CrossrefPubMedGoogle Scholar
  • 18 Naimi T S, LeDell K H, Como-Sabetti K et al.. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection.  JAMA. 2003;  290 2976-2984
    CrossrefPubMedGoogle Scholar
  • 19 Chickering H T, Park J H. Staphylococcus aureus pneumonia.  JAMA. 1919;  72 617-626
    PubMedGoogle Scholar
  • 20 Ede S, Davis G M, Holmes F H. Staphylococcic pneumonia.  JAMA. 1959;  170 638-643
    PubMedGoogle Scholar
  • 21 Reimann H A. Primary staphylococcic pneumonia.  JAMA. 1933;  101 514-520
    PubMedGoogle Scholar
  • 22 Gallis H A. Subacute staphylococcal pneumonia in renal transplant recipient.  Am Rev Respir Dis. 1975;  112 109-112
    PubMedGoogle Scholar
  • 23 Watanakunakorn C. Bacteremic Staphylococcus aureus pneumonia.  Scand J Infect Dis. 1987;  19 623-627
    PubMedGoogle Scholar
  • 24 Wiita R M, Cartwright R R, Davis J G. Staphylococcal pneumonia in adults: a review of 102 cases.  Am J Roentgenol. 1961;  86 1083-1091
    PubMedGoogle Scholar
  • 25 Bentley D W. Staphylococcal pneumonia: coping with a medical emergency.  J Respir. 1980;  1 23-41
    PubMedGoogle Scholar
  • 26 Naraqi S, McDonnell G. Hematogenous staphylococcal pneumonia secondary to soft tissue infection.  Chest. 1981;  79 173-175
    PubMedGoogle Scholar
  • 27 Musher D M, Franco M. Staphylococcal pneumonia: a new perspective.  Chest. 1981;  79 172-173
    PubMedGoogle Scholar
  • 28 Fisher A M, Trever R W, Curtin J A et al.. Staphylococcal pneumonia: a review of 21 cases in adults.  N Engl J Med. 1958;  256 919-928
    PubMedGoogle Scholar
  • 29 Johnston B L. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia: a critical review.  Semin Respir Infect. 1994;  9 199-206
    PubMedGoogle Scholar
  • 30 Cafferkey M T, Abrahamson E, Bloom A et al.. Pulmonary infection due to methicillin-resistant Staphylococcus aureus .  Scand J Infect Dis. 1988;  20 297-301
    PubMedGoogle Scholar
  • 31 Gonzalez C, Rubio M, Romero-Vivas J et al.. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.  Clin Infect Dis. 1999;  29 1171-1177
    CrossrefPubMedGoogle Scholar
  • 32 Rello J, Torres A, Ricart M et al.. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes.  Am J Respir Crit Care Med. 1994;  150 1545-1549
    CrossrefPubMedGoogle Scholar
  • 33 Healy C M, Hulten K G, Palazzi D L et al.. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit.  Clin Infect Dis. 2004;  39 1460-1466
    CrossrefPubMedGoogle Scholar
  • 34 Francis J S, Doherty M C, Lopatin U et al.. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.  Clin Infect Dis. 2005;  40 100-107
    PubMedGoogle Scholar
  • 35 Dufour P, Gillet Y, Bes M et al.. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: Emergence of a single clone that produces Panton-Valentine leukocidin.  Clin Infect Dis. 2002;  35 819-824
    CrossrefPubMedGoogle Scholar
  • 36 Kravitz G R, Dries D J, Peterson M L et al.. Purpura fulminans due to Staphylococcus aureus .  Clin Infect Dis. 2005;  40 941-947
    CrossrefPubMedGoogle Scholar
  • 37 Gillet Y, Issartel B, Vanhems P et al.. Association between lethal Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients.  Lancet. 2002;  359 753-759
    CrossrefPubMedGoogle Scholar
  • 38 Boussaud V, Parrot A, Mayaud C et al.. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus .  Intensive Care Med. 2003;  29 1840-1843
    CrossrefPubMedGoogle Scholar
  • 39 Le Thomas I, Mariani-Kurkdjian P, Collignon A et al.. Breast milk transmission of a Panton-Valentine leukocidin-producing Staphylococcus aureus strain causing infantile pneumonia.  J Clin Microbiol. 2001;  39 728-729
    CrossrefPubMedGoogle Scholar
  • 40 Hsu L-Y, Koh T-H, Kurup A et al.. High incidence of Panton-Valentine leukocidin-producing Staphylococcus aureus in a tertiary care public hospital in Singapore.  Clin Infect Dis. 2005;  40 486-489
    CrossrefPubMedGoogle Scholar
  • 41 Panton P N, Valentine F CO. Staphylococcal toxin.  Lancet. 1932;  1 506-508
    PubMedGoogle Scholar
  • 42 Lina G, Piemont Y, Godall-Gamot F et al.. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.  Clin Infect Dis. 1999;  29 1128-1132
    CrossrefPubMedGoogle Scholar
  • 43 Chambers H F. Staphylococcal purpura fulminans: a toxin-mediated disease?.  Clin Infect Dis. 2005;  40 948-950
    CrossrefPubMedGoogle Scholar
  • 44 Miller L G, Perdreau-Remington F, Rieg G et al.. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.  N Engl J Med. 2005;  352 1445-1453
    CrossrefPubMedGoogle Scholar
  • 45 Fowler V G, Li J, Corey R G et al.. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.  J Am Coll Cardiol. 1997;  30 1072-1078
    CrossrefPubMedGoogle Scholar
  • 46 Moise P A, Schentag J J. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infection.  Int J Antimicrob Agents. 2000;  16 S31-S34
    PubMedGoogle Scholar
  • 47 Georges H, Leroy O, Alfandari S et al.. Pulmonary disposition of vancomycin in critically ill patients.  Eur J Clin Microbiol Infect Dis. 1997;  16 385-388
    CrossrefPubMedGoogle Scholar
  • 48 Moellering R C. Linezolid: the first oxazolidinone antimicrobial.  Ann Intern Med. 2003;  138 135-142
    PubMedGoogle Scholar
  • 49 Stevens D L, Herr D, Lampiris H et al.. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.  Clin Infect Dis. 2002;  34 1481-1490
    CrossrefPubMedGoogle Scholar
  • 50 Kollef M H, Rello J, Cammarata S K et al.. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.  Intensive Care Med. 2004;  30 388-394
    PubMedGoogle Scholar
  • 51 Rubinstein E, Cammarata S K, Oliphant T H et al.. Linezolid (PNU-10076) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.  Clin Infect Dis. 2001;  32 402-412
    CrossrefPubMedGoogle Scholar
  • 52 Wunderink R G, Rello J, Cammarata S K et al.. Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2003;  124 1789-1797
    CrossrefPubMedGoogle Scholar
  • 53 Powers J H, Ross D B, Lin D et al.. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2004;  126 314-316
    CrossrefPubMedGoogle Scholar
  • 54 Eliopoulos G M. Quinupristin-dalfopristin and linezolid: evidence and opinion.  Clin Infect Dis. 2003;  36 473-481
    CrossrefPubMedGoogle Scholar
  • 55 Fagon J- Y, Patrick H, Haas D W et al.. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin.  Am J Respir Crit Care Med. 2000;  161 753-762
    CrossrefPubMedGoogle Scholar
  • 56 Scotton P G, Rigoli R, Vaglia A. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens.  Infection. 2002;  30 161-163
    CrossrefPubMedGoogle Scholar
  • 57 Carpenter C F, Chambers H F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.  Clin Infect Dis. 2004;  38 994-1000
    CrossrefPubMedGoogle Scholar
  • 58 Adra M, Lawrence K R. Trimethoprim-sulfamethoxazole for treatment of severe Staphylococcus aureus infections.  Ann Pharmacother. 2004;  38 338-341
    PubMedGoogle Scholar
  • 59 Ruhe J J, Monson T, Bradsher R W, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature.  Clin Infect Dis. 2005;  40 1429-1434
    CrossrefPubMedGoogle Scholar
  • 60 Lewis J S, Jorgensen J H. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned.  Clin Infect Dis. 2005;  40 280-285
    CrossrefPubMedGoogle Scholar
  • 61 Gauduchon V, Cozon G, Vandenesch F et al.. Neutralization of Staphylococcus aureus Panton-Valentine leukocidin by intravenous immunoglobulin in vitro.  J Infect Dis. 2004;  189 346-353
    CrossrefPubMedGoogle Scholar

Suzanne F BradleyM.D. 

Infectious Diseases Section, GRECC 11G, VA Ann Arbor Healthcare System, 2215 Fuller Rd., Ann Arbor, MI 48105

Email: sbradley@umich.edu

      >